Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Schoenberg

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The Journal of Urology|December 21, 2010
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancerGuru Sonpavde, Myrna M Khan, Seth P Lerner, et al.
The Journal of Urology|July 21, 2010
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patientsDerya Tilki, Robert S Svatek, Giacomo Novara, et al.
The Journal of Urology|April 20, 2010
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patientsGiacomo Novara, Robert S Svatek, Pierre I Karakiewicz, et al.
The Journal of Urology|November 28, 2009
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patientsDerya Tilki, Robert S Svatek, Pierre I Karakiewicz, et al.
European Urology|September 22, 2009
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohortHans-Martin Fritsche, Maximilian Burger, Robert S Svatek, et al.
European Urology|June 20, 2015
Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]Hans-Martin Fritsche, Maximilian Burger, Robert S Svatek, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
The Journal of Urology|January 5, 2022
Reply by AuthorsSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
The Journal of Urology|December 17, 2021
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final ReportSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
The Lancet. Oncology|July 8, 2020
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trialNir Kleinmann, Surena F Matin, Phillip M Pierorazio, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Journal of Urology|December 21, 2010
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancerGuru Sonpavde, Myrna M Khan, Seth P Lerner, et al.
The Journal of Urology|July 21, 2010
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patientsDerya Tilki, Robert S Svatek, Giacomo Novara, et al.
The Journal of Urology|April 20, 2010
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patientsGiacomo Novara, Robert S Svatek, Pierre I Karakiewicz, et al.
The Journal of Urology|November 28, 2009
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patientsDerya Tilki, Robert S Svatek, Pierre I Karakiewicz, et al.
European Urology|September 22, 2009
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohortHans-Martin Fritsche, Maximilian Burger, Robert S Svatek, et al.
European Urology|June 20, 2015
Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]Hans-Martin Fritsche, Maximilian Burger, Robert S Svatek, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
The Journal of Urology|January 5, 2022
Reply by AuthorsSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
The Journal of Urology|December 17, 2021
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final ReportSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
The Lancet. Oncology|July 8, 2020
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trialNir Kleinmann, Surena F Matin, Phillip M Pierorazio, et al.
Pageof 7